CMS Open Payments · Program Year 2024
Prytime Medical Devices, Inc.
Prytime Medical Devices, Inc. reported $1,070,379.04 across General Payments, Research, and Ownership to 311 physicians and teaching hospitals across 373 transactions.
- $1.1M
- All-tracks total
- 373
- Transactions
- 311
- Recipients
- +$12.2K
- General Payments vs PY2023
Prytime Medical Devices, Inc. reported $1,070,379.04 across all CMS Open Payments tracks (General + Research + Ownership) to 311 physicians and teaching hospitals in Program Year 2024 - ranking #605 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $265,721.89, averaging $3.4K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer prytime-medical-devices-inc Prytime Medical Devices, Inc.
$1.1M · #605/1,925 · 0.0% industry · PY2024
- TOT $1.1M
- RANK #605
- SHARE 0.0%
- TXN 373
- RCP 311
- CAT 4
- GEN $265.7K
- ΔGEN +$12.2K
- TOP1 60.0%
- PY 2024
Volume peers
Nearest volume peer: Verrica Pharmaceuticals Inc. ($1.1M)
Prytime Medical Devices, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Prytime Medical Devices, Inc.'s CMS-reported General Payments increased by $12.2K (+4.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PRYTIME MEDICAL DEVICES, INC.PY2023: PRYTIME MEDICAL DEVICES, INC.PY2024: Prytime Medical Devices, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $253,526.00
- PY2024
- $265,721.89
What the Data Shows for Prytime Medical Devices, Inc.
$1,070,379.04: that is what Prytime Medical Devices, Inc. reported in payments to 311 physicians and teaching hospitals during Program Year 2024, spread across 373 transactions ($2.9K per transaction, $3.4K per recipient). The company sits at rank #605 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $202.5K, accounting for 76.2% of this company's General Payments and 15 transactions.
General Payment Breakdown by Type
Prytime Medical Devices, Inc. made 4 types of general payments. "Consulting Fee" is the largest category at $202.5K, 76.2% of General Payments.
Prytime Medical Devices, Inc. reports 4 general-payment categories - the top three are Consulting Fee (76.2%), Travel and Lodging (12.2%), and Food and Beverage (7.7%). The remaining 1 category make up 3.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Prytime Medical Devices, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $202.5K | 15 | 76.2% |
| Travel and Lodging | $32.4K | 30 | 12.2% |
| Food and Beverage | $20.4K | 262 | 7.7% |
| Compensation for Faculty or Speaker (Medical Education) | $10.4K | 4 | 3.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $238,581.94 (89.8%) of $265,721.89 in this company's General Payments records across 176 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Prytime Medical Devices, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Marshall Spalding
$159,343.67 across 24 reported transactions
- 2
Todd Rasmussen
$45,653.71 across 6 reported transactions
- 3
Jonathan Nguyen
$26,301.38 across 27 reported transactions
- 4
James a Betz
$4,669.80 across 6 reported transactions
- 5
Robert Cohen
$2,613.38 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Prytime Medical Devices, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Prytime Medical Devices, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Prytime Medical Devices, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Innovasis Inc
Grifols Therapeutics LLC
Bionova Medical Inc
ZOLL Circulation Inc
Cerapedics Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.